Rethinking HDL

A new understanding of HDL, driven by studies and assays produced in academia, has narrowed down the biological processes drug developers should tackle to modulate the much-maligned cardiovascular target.

HDL first hit the radar screen when large population-based studies provided evidence that higher levels of HDL seemed to lead to less mortality and better outcomes. But thus far, raising HDL with therapeutics has been benign at best...